» Articles » PMID: 35001799

Yi Shen An, a Chinese Traditional Prescription, Ameliorates Membranous Glomerulonephritis Induced by Cationic Bovine Serum Albumin in Rats

Overview
Journal Pharm Biol
Specialties Pharmacology
Pharmacy
Date 2022 Jan 10
PMID 35001799
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Yi Shen An (YSA) is an investigational composite of traditional Chinese medicine (Reference: 2010L000974) for the treatment of renal disease.

Objective: To investigate the protective effects of YSA against membranous glomerulonephritis (MGN).

Materials And Methods: Male Sprague-Dawley rats were injected with cationic bovine serum albumin (C-BSA) to create a model of MGN. Then, rats were orally treated with YSA at doses of 0.25, 0.5, 1 and 2 g/kg for 35 successive days; prednisone (5 mg/kg) was used as a positive control. At the end of the experimental period, we performed a series of tests, including 24 h urinary protein, and biochemical, immunological, antioxidative, coagulation indices, and histopathological examination.

Results: YSA-1 g/kg significantly lowered urinary protein from 68.37 to 30.74 mg ( < 0.01). Meantime, total protein (TP) and albumin (ALB) recovered from 66.26 and 20.51 g/L to 76.08 and 35.64 g/L ( < 0.01), respectively. YSA removed the deposition of immunoglobulin G (IgG) and complement 3c (C3c), prevented inter-capillary cell hyperplasia on the glomerular basement membrane (GBM), and reduced electron-dense deposits and fusion of podocytes. In addition, serum IgG and superoxide dismutase were significantly elevated. In contrast, malondialdehyde, total cholesterol, triglyceride, circulating immune complex (CIC), and immunoglobulin M decreased in the YSA-treated group. Moreover, the blood coagulation dysfunction was adjusted.

Discussion And Conclusions: These findings indicate YSA may exert a therapeutic effect against MGN through the inhibition of CIC formation, and the removal of IgG and C3c deposition from the GBM, thus supporting the development of further clinical trials.

Citing Articles

Safranal Ameliorates Renal Damage, Inflammation, and Podocyte Injury in Membranous Nephropathy via SIRT/NF-κB Signalling.

Bao Y, Ge Y, Wang Z, Wang H, Wang Q, Yuan J Curr Med Sci. 2025; .

PMID: 40035996 DOI: 10.1007/s11596-025-00020-8.


Barleriside A, an aryl hydrocarbon receptor antagonist, ameliorates podocyte injury through inhibiting oxidative stress and inflammation.

Li X, Wang Y, Wang W, Nie X, Miao H, Zhao Y Front Pharmacol. 2024; 15:1386604.

PMID: 39239643 PMC: 11374728. DOI: 10.3389/fphar.2024.1386604.


Diosgenin protects against cationic bovine serum albumin-induced membranous glomerulonephritis by attenuating oxidative stress and renal inflammation via the NF-κB pathway.

Jia S, Si R, Liu G, Zhong Q Pharm Biol. 2024; 62(1):285-295.

PMID: 38516898 PMC: 10962310. DOI: 10.1080/13880209.2024.2330602.

References
1.
Couser W . Mechanisms of glomerular injury in immune-complex disease. Kidney Int. 1985; 28(3):569-83. DOI: 10.1038/ki.1985.167. View

2.
Stancliffe R, Thorpe T, Zemel M . Dairy attentuates oxidative and inflammatory stress in metabolic syndrome. Am J Clin Nutr. 2011; 94(2):422-30. PMC: 3142721. DOI: 10.3945/ajcn.111.013342. View

3.
Llach F . Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int. 1985; 28(3):429-39. DOI: 10.1038/ki.1985.149. View

4.
Howman A, Chapman T, Langdon M, Ferguson C, Adu D, Feehally J . Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013; 381(9868):744-51. PMC: 3590447. DOI: 10.1016/S0140-6736(12)61566-9. View

5.
Pavenstadt H, Kriz W, Kretzler M . Cell biology of the glomerular podocyte. Physiol Rev. 2002; 83(1):253-307. DOI: 10.1152/physrev.00020.2002. View